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HSV-1 ampliconsFriedreich's ataxia (FRDA) is the most common form of hereditary ataxia caused by recessive mutations in the
FXN gene. Recent results have indicated the presence of different frataxin isoforms due to alternative gene ex-
pression mechanisms. Our previous studies demonstrated the advantages of using high-capacity herpes simplex
virus type 1 (HSV-1) amplicon vectors containing the entire FXN genomic locus (iBAC-FXN) as a gene-delivery
vehicle capable of ensuring physiologically-regulated and long-term persistence. Here we describe how expres-
sion from the 135 kb human FXN genomic locus produces the three frataxin isoforms both in cultured neuronal
cells and also in vivo. Moreover, we also observed the correct expression of these frataxin isoforms in patient-
derived cells after delivery of the iBAC-FXN. These results lend further support to the potential use of HSV-1
vectors containing entire genomic loci whose expression is mediated by complex transcriptional and posttran-
scriptional mechanisms for gene therapy applications.
© 2015 Elsevier Inc. All rights reserved.1. Introduction
Friedreich's ataxia (FRDA, [OMIM 229300]), the most common form
of hereditary ataxia, is a predominantly neurodegenerative disease af-
fecting certain neurons at the dorsal root ganglia, the spinal cord, the
brainstem and the cerebellum. Neurodegeneration occurs ﬁrst in the
dorsal root ganglia, with loss of large proprioceptive neurons, followed
by degeneration of posterior columns and corticospinal tracts of the spi-
nal cord and the dentate nucleus in the cerebellum [17]. The onset of the
disease usually occurs before adolescence, although in some cases it can
start in adulthood or even later [29]. Symptoms include progressive
limb and gait ataxia, as well as dysarthria, tendon areﬂexia, sensory
loss, and pyramidal signs. The most important extra-neurological man-
ifestationswhichmay appear are hypertrophic cardiomyopathy, follow-
ed by glucose intolerance and diabetes mellitus [29].
From a genetic point of view, FRDA is an autosomal recessive disease
caused bymutations in the FXN gene [8]. This gene [MIM606829], locat-
ed at chromosome 9q21.11, encodes a protein known as frataxin, which
is highly conserved and ubiquitous with its highest expression in
mitochondria-rich tissues including the nervous system, heart andular “Severo Ochoa”, C/Nicolas
.muscle [19]. In most patients, the mutation responsible for the disease
involves the expansion of a trinucleotide GAA repeat located in the
ﬁrst intron of the gene [5] leading to a reduction in the expression of
frataxin [4,45].
Frataxin is mainly localised in the mitochondria [19]. The protein is
synthesised as a precursor form which is subsequently imported to
themitochondria,where it undergoes consecutive proteolytic cleavages
by the mitochondrial processing peptidase (MPP) to produce the ma-
ture form [11]. There are different biological functions in which frataxin
appears to play an important role including iron homeostasis, iron–sul-
phur cluster biosynthesis, modulation of oxidative phosphorylation and
regulation of the response to oxidative stress, but we still do not know
how frataxin deﬁciency triggers the neurodegenerative process associ-
ated with the disease [for a review of frataxin function, see [3,40]].
The frataxin gene is known to generate several transcripts [5,33]. In-
terestingly, a recent report has highlighted the existence of two novel
frataxin isoforms (FXN II and FXN III) which lack the mitochondrial
targeting sequence and may also play a role in the pathogenesis of
FRDA [44]. Thus, in addition to the canonical frataxin (FXN I) form
which is found within mitochondria, FXN III, generated by alternative
splicing, is localised to cell nuclei and FXN II, generated by a different
transcription start site, is present in the cytosol [44]. Interestingly the
expression of FXN II is particularly signiﬁcant in the nervous tissue in-
cluding the cerebellum whereas FXN III seems more enriched in the
heart [44].
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of the frataxin protein, gene therapy appears to be a promising alterna-
tive treatment [9,20]. A pioneering study in FRDA demonstrated that
both adeno-associated viral (AAV) and lentiviral (LV) vectors coding
for frataxin cDNA were able to partially rescue the phenotype of ﬁbro-
blasts derived from FRDA patients [10]. However, total restoration of
the normal phenotype was not achieved, and it was suggested that
this might be due to the fact that frataxin expression over physiological
levels may be toxic [10]. Later, our group demonstrated that a herpes
simplex virus type 1 (HSV-1) amplicon vector coding for frataxin
cDNA was able to reverse the neurological defects observed in a FRDA
mouse model [21]. In this case, the level of frataxin protein expressed
by the HSV vector was similar to the physiological levels observed in
wild-type neurons [21]. More recently, Perdomini and colleagues re-
ported the prevention and reversal of severe cardiomyopathy by gene
therapy using an AAV vector coding for frataxin cDNA in a mouse
model with complete frataxin deletion in cardiac and skeletal muscle
[30]. This study highlighted the rescue of the cardiomyocyte phenotype
even after the onset of cardiac failure, which is extremely encouraging
and establishes preclinical proof of concept for the potential of gene
therapy to treat FRDA cardiomyopathy. Interestingly, no deleterious ef-
fects due to frataxin overexpressionwere observed.Whether this is due
to cell type or species differences remains to be established. In all these
studies, the vectors used contained the cDNA coding for the convention-
al mitochondrial frataxin (FXN I), suggesting that this isoform is crucial
for both the development and the recovery of the pathology. However
the possibility of a signiﬁcant contribution of the other isoforms to the
pathology of FRDA cannot be ruled out.
We previously reported that a 135 kb BAC containing approximately
38 kb of intact promoter region, the 80 kb frataxin gene locus, and 17 kb
of downstream sequence can be efﬁciently packaged into HSV-1 parti-
cles (iBAC-FXN) [13] using a helper virus-free packaging system [36].
This genomic region contains all the regulatory elements of frataxin
gene expression identiﬁed so far [35]. Furthermore, FRDA patient ﬁbro-
blasts transduced with this iBAC-FXN vector showed a physiological
level of frataxin expression and functional restoration of the wild-type
cellular phenotype in response to oxidative stress [13]. The same con-
struction was used in an assay to demonstrate the long-term persis-
tence of gene expression after the injection of the iBAC-FXN vector
into the mouse cerebellum in vivo [12].
In this work, we have used this HSV-1 amplicon vector (iBAC-FXN)
to deliver the entire FXN genomic locus to test for the expression of
the different frataxin isoforms both in vitro in cultured cells and
in vivo after the intracranial injection of HSV vectors into the adult
mouse cerebellum.
2. Materials and methods
2.1. BACs and HSV-1 amplicons used
The fully sequenced BACRP11-265B8 obtained from theBACPAC Re-
sources Center (http://bacpac.chori.irg), modiﬁed as described else-
where [13] was used. For the transduction experiments, we used
pHG-FRDA [13], which comprises the BAC containing thewhole frataxin
genomic locus supplied with the different elements needed for packag-
ing into herpes viral particles.
2.2. Cell culture
Neuro-2A (N2A) mouse neuroblastoma cells (ATCC CCL131,
American Type Culture Collection, Rockville, MD) were routinely
grown in Dulbecco's modiﬁed Eagle medium (DMEM) supplemented
with 10% heat-inactivated FBS (Invitrogen, Life Technologies, Barcelona,
Spain) containing 2 mM L-glutamine and penicillin/streptomycin
(100 U/ml and 100 μg/ml, respectively), in a humidiﬁed incubator at
37 °C in 5% CO2.Human olfactorymucosa stemcells (OMSCs)were obtained frombi-
opsies of healthy subjects and from patients with FRDA [26]. Cells were
cultured in 2% CSC medium (DMEM/F12 (Invitrogen)) supplemented
with 0.5% (w/v) Albumax I (Invitrogen), 0.5% HEPES 1 M (Invitrogen),
0.6% (w/v) glucose (Sigma, Madrid, Spain), 2% foetal bovine serum
(Sigma), 1% N2 (Invitrogen), 1% non-essential amino acids, 0.1% penicil-
lin/streptomycin and freshly added 8 ng/ml recombinant human ﬁbro-
blast growth factor-2 (rhFGF-2, PeproTech, Rocky Hill, NJ, USA) and
50 ng/ml nerve growth factor (NGF, Sigma) at 37 °C in 5% CO2. The de-
tailed characterisation of human OMSC lines will be described in anoth-
er paper (manuscript in preparation). Experimentation on human
subjects to obtain the olfactory mucosa biopsies were performed ac-
cording to the Code of Ethics of theWorldMedical Association (Declara-
tion of Helsinki) after approval by the Ethics Committee and informed
consent from all the donors.
2.3. Production and transduction of HSV-1 amplicons
The pHG-FRDA vector (referred to here as the infectious bacterial ar-
tiﬁcial chromosome, or iBAC-FXN, vector)was packaged intoHSV-1 par-
ticles using an improved HSV-1 helper virus-free system as described
previously [36,42]. Typically, the supernatant from three 6-cm dishes
was concentrated and re-suspended in 250 ml DMEM supplemented
with 10% FCS to give a stock of 1–3 × 107 transducing units ml−1
when tittered for GFP expression on a conﬂuent G16-9 cell layer. G16-
9 cells, a derivative of the human Gli-36 glioma cell line expressing
the HSV-1 VP16 protein to enhance expression from the pIE4/5-GFP
promoter cassette, were cultured in Dulbecco's modiﬁed Eagle medium
supplemented with 10% (v/v) foetal calf serum 100 U ml−1 penicillin,
100 μg ml−1 streptomycin and hygromycin-B (200 μg ml−1).
For amplicon infection, 1–2 × 106 cells were plated onto a p100 and
24 h later, transducedwith theHSV-1 amplicon for an additional 24 h in
8 ml medium. After transduction, the amplicon mixture was removed,
and 8 ml of fresh media was added to the cells. The infection was
prolonged for an additional 24 h and the cells were then harvested to
perform either RT-PCR or western blotting.
2.4. Stereotaxic injection
Eight-week-old male C57BL/6 mice (Charles River breeding Labora-
tories, Barcelona, Spain) were used in this study. Themice were housed
in a temperature-controlled room under a 12-h light/12-h dark cycle.
Brieﬂy, the mice were anesthetised with isoﬂurane and placed in a ste-
reotaxic frame (Stoelting,WoodDale, IL, USA) for injection of 3ml of the
vector iBAC-FXN (7 × 106 transducing units ml−1) into the cerebellum
(AP: 6.5, lateral: 2.0; V: 2.0) over 3 min using a 5 ml Hamilton syringe.
At the end of the experiment, the skin was sutured and the anaesthesia
was discontinued. The mice were kept in individual cages with water
and food ad libitum, and observed periodically in the following days.
Micewere anesthetised at 0, 2, and 7 dayswith CO2, decapitated and
the cerebellum was dissected and collected in RNAse-free polypropyl-
ene tubes, immediately frozen in liquid nitrogen and stored at−80 °C
until further use. The animal study and protocol were approved by the
Institutional Animal Care and Use Committee at the Centro de Biología
Molecular and followed European Directive 2010/63/EU. All efforts
were made to minimize suffering and the numbers of animals used.
2.5. RT-PCR
RT-PCR analysis of FXN expression was performed in the mouse
N2A cells, the patient-derived olfactory stem cells, and the mouse
cerebellum.
Total RNAwas preparedusing the RNeasyMini Kit (Qiagen, Limburg,
Netherlands) according to the manufacturer's protocol, with additional
on-column DNAse digestion (Qiagen). The RNA concentration was
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tegrity checked by electrophoresis in 1% agarose gel.
First strand cDNA was synthesised from 3 μg of total RNA using
Superscript III reverse transcriptase (Invitrogen) according to the
manufacturer's protocol. For each sample we perform a cDNA synthesis
with and without retrotranscriptase to ensure non-genomic DNA was
being ampliﬁed.
Isoform ampliﬁcations were performed in a 25-μl PCR using 1 μl of
the resulting cDNA using the same primers as described by Xia and col-
leagues [44], except for the ampliﬁcation of isoform III, for which a spe-
ciﬁc forward primer was designed spanning exon1AΔ141/exon 2
junction (5′-GGCGCCGCGCAGTTCGAACC-3′). Fig. 1A is a schematic rep-
resentation of the three frataxin isoforms showing the localisation of the
primers used. As internal controls we used, GAPDH-Fw (5′-TGAAGGTC
GGAGTCAACGGATTTGGT-3′) and GAPDH-Rv (5′-CATGTGGGCCATGAFig. 1.Delivery of the frataxin gene tomouse neuroblastoma cells in vitro.Mouse neuro-2A (N2A
locus (iBAC-FXN) and RNAwas prepared for the analysis of FXN isoform expression. (A) Schema
used for their ampliﬁcation. (B) Diagram showing the FXN-containing BAC used and its packagin
with speciﬁc primers for human frataxin showing the expression of all frataxin isoforms inN2A
PCR reactions; (+): cDNA used as template for PCR ampliﬁed with RT enzyme; (−): cDNA use
(in base pairs) of marker bands.GGTCCACCAC) to amplify a fragment of 900 bp of murine GAPDH or
βActin-Fw (5′-CCACACTGTGCCCATCTACGAGGGGT-3′) and βActin-Rv
(5′-AGGGCAGTGATCTCCTTCTGCATCCT-3′) to amplify a fragment of
479 bp of human actin. All the pictures presented are representatives
of three independent experiments.
2.6. Cell lysis, subcellular fractionation and western blotting
The cells were washed twice with phosphate-buffered saline (PBS),
harvested, placed on ice and then homogenised in a buffer containing
20 mM 4-(2-hydroxyethyl) piperazine-1-ethanesulfonic acid (HEPES)
[pH 7.4], 100 mM sodium chloride (NaCl), 100 mM sodium ﬂuoride
(NaF), 1% Triton X-100, 1 Mm sodium orthovanadate (Na3VO4), 5 mM
ethylenediaminetetraacetic acid and the COMPLETE™ protease inhibi-
tor cocktail (Roche Diagnostics, Barcelona, Spain). The soluble fraction) cellswere transducedwith a HSV-1 amplicon harbouring the complete frataxin genomic
tic representation of the different frataxin isoforms showing the localisation of the primers
g into herpes viral particles using the helper-freemethod described elsewhere. (C) RT-PCR
cells transducedwith iBAC-FXN. M: 1 kb ladder (Invitrogen); PCR−ve: negative control for
d as template for PCR ampliﬁed without RT enzyme. Numbers to the right indicate the size
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quently, samplesweremixedwith electrophoresis buffer containing so-
dium dodecyl sulphate (SDS), boiled for 5 min and separated by gel
electrophoresis in the presence of SDS on 8–15% acrylamide–
bisacrylamide gels. The proteins were then electrotransferred to nitro-
cellulosemembranes (Schleicher & Schuell, Dassel, Germany) following
standard procedures, and the membranes were subsequently blocked
with 10% non-fat dried milk in PBS plus 0.2% Tween-20 (PBST). The
blockedmembraneswere incubated overnight with primary antibodies
diluted in blocking solution at 4 °C and the ﬁlters were then rinsed in
PBST at least three times. After incubation with the corresponding
peroxidase-conjugated secondary antibody for 1 h at room tempera-
ture, antibody binding was visualized using an enhanced chemilumi-
nescence detection system (GE Healthcare, Little Chalfont, United
Kingdom).
Cytosolic, mitochondrial and nuclear fractions were obtained using
the Cell Fractionation Kit (MS861, MitoSciences, Abcam, Cambridge,
UK) following the manufacturer's recommendations. Brieﬂy, control
cells and patients' cells were grown to conﬂuence in a 100 mm tissue
culture plate and then trypsinized and collected by centrifugation.
After being washed with Buffer A, the cells were resuspended to a con-
centration of 6.6 × 106 cells ml−1 and cellular extractions obtained after
two sequential detergent-extraction steps. The purity of the fractions
was assessed by western blotting against Lamin B1 (nuclear), β-
tubulin (cytoplasmic) and COX-V (mitochondrial) proteins. All the
western-blotting showed are representative of at least three different
experiments.
The following antibodieswere used forwestern blotting: a polyclon-
al antisera against human frataxin (R6.3s, 1:1000) raised against the
peptide TLGHPGSLDETTYERLAEETLC (Protein Tools, Madrid, Spain),
previously described by Palomo and colleagues [28], polyclonal anti-
bodies against Lamin B1 (1:1000; Santa Cruz Biotechnology, Santa
Cruz, CA, USA); anti-OxPhos complex V subunit β (1:1000; Molecular
Probes, Eugene, OR, USA), and monoclonal antibodies against β-
tubulin (1:1000; Sigma).
3. Results
In this work, we have checked whether a BAC containing the whole
frataxin genomic locus is able to produce the three frataxin isoforms
which have been recently described [44]. We ﬁrst assessed the expres-
sion of these isoforms in the mouse neuroblastoma N2A cell line as tar-
get cells. The iBAC-FXN used in this study (derived from theRP11-265B8
BAC clone) contains the 80 kb frataxin genomic locus plus 38 kb up-
stream and 17 kb downstream and is supplied with the elements need-
ed to be packaged into herpes viral particles [13] (Fig. 1B). For the
packaging of theHSV-1 virions, we used a helper-free packaging system
consisting in triple transfection into Vero 2-2 packaging cells [36]. Our
group has already demonstrated that HSV-1 amplicons expressing
whole genomic loci provide sustained expression of the transgene ei-
ther in vitro or in vivo [12,13], but we wished to test whether this con-
struct contained all the regulatory elements needed to produce the
different frataxin isoforms. For this experiment, cells were transduced
with HSV-1 amplicons containing iBAC-FXN. Forty-eight hours post-
transduction, we performed reverse transcription-polymerase chain re-
action (RT-PCR) to detect ampliﬁcation of the frataxin isoforms. As
shown in Fig. 1C, all three frataxin isoforms were ampliﬁed in N2A
cells upon transduction with the whole genomic locus, showing for
the ﬁrst time that it is possible to express all frataxin isoforms using
the iBAC-FXN genomic locus vector.
Frataxin isoforms mainly differ in the ﬁrst exon, being identical
from exons 2 to 5. For the ampliﬁcation of all of them we used the
same primers already described [44], with the exception of isoform III
(see Section 2.5.). Fig. 1A shows a schematic representation of three
frataxin isoform and the localisation of the primers used for their ampli-
ﬁcation (Supplementary Fig. 1 shows a schematic representation offrataxin isoforms whereas the corresponding sequence alignments
are shown in Supplementary Figs. 2 and 3). As the primers for amplify-
ing the three isoforms are human-speciﬁc, no ampliﬁcation of endoge-
nous mouse frataxin isoforms was observed in N2A neuroblastoma
cells.
We next checkedwhether the iBAC-FXN vector was also able to pro-
duce all frataxin isoforms in vivo. For this purpose, we used stereotaxic
injection into the cerebellum of adult C57BL/6 mice to deliver the iBAC-
FXN. As frataxin expression reaches its highest levels between 24 and
48 h post-injection [12], the mice were killed at day 2 and day 7, using
amouse thatwas killed just after injection as control (0day). Expression
of the three isoformswas detected by RT-PCR as soon as 2 days after in-
jection, and expression persisted up to 7 days, the last day of our exper-
iment (Fig. 2). Expression for isoforms I and III was observed to be
qualitatively higher at day 7 than at day 2, providing evidence of in-
creased expression over time, although for isoform II the increase was
not so clear.
Our laboratory has previously isolated human olfactory mucosa
stem cells (OMSCs) from FRDA patients and healthy donors [26].
Using these OMS cells, we next investigated the amount of all frataxin
isoforms expressed by these cells in both control (C3c) and FRDA pa-
tient cells. Human FRDA patient cells expressed low levels of both FXN
mRNA and protein, so we decided to characterise isoform gene expres-
sion in OMS cells from two different FRDA patients (AF1 and AF6) and
compare them with their expression in OMS cells from a healthy
donor (C3c). The analysis of frataxin isoform mRNA revealed the pres-
ence of isoforms I, II and III both in control and patient-derived cells
(Fig. 3A), with isoform II almost undetectable in AF6 cells (Fig. 3A). As
PCR data are not quantitative, we also examined the expression of
frataxin protein isoforms by western blotting after performing cellular
fractionation to obtain isolated cytosolic, mitochondrial, and nuclear
fractions (Fig. 3B). We observed that C3c cells presented all frataxin iso-
forms in the different compartments whereas AF1 and AF6 contained
signiﬁcantly reduced levels of all them. The predominantly expressed
frataxin isoformwas the FXN I-derivedmature form in themitochondri-
al fraction. The level of this mitochondrial frataxin was much higher in
control C3c cells than in FRDA patient-derived AF1 and AF6 cells. Curi-
ously AF6 cells expressedmuch lower levels of FXN I-derived precursor
protein at the cytosol than either C3c or AF1 cells. A low level of mature
frataxin (which is presumably derived from FXN IImRNA)was detected
in the cytosol of control cells. Cytosolic mature frataxin was hardly de-
tectable in FRDA-derived patient cells. Nuclear frataxin (which presum-
ably comes from FXN III mRNA) consists of several bands of an apparent
molecularmass larger than that corresponding tomaturemitochondrial
frataxin. The occurrence of several bands probably reﬂects the presence
of degradation products which may arise from iron-mediated self-
cleavage as previously suggested [44]. Again nuclear frataxinwas hardly
detectable in FRDA-derived patient cells.
Finally, we transduced OMS cells with the frataxin genomic con-
struct in order to test whether the BACwas able to reconstitute frataxin
levels in FRDA patient cells. OMS cells from a FRDA patient (AF6) were
harvested 48 h post-transduction with iBAC-FXN and tested for mRNA
and protein level expression, using non-transduced OMS cells from
AF6 as control. Frataxin-deﬁcient OMS cells from patient AF6 had in-
creased mRNA expression of all frataxin isoforms compared with non-
transduced control cells after two days of transduction with the iBAC-
FXN (Fig. 4A). As for the sub-cellular localisation of the isoforms,
western blot analysis of the compartment lysates showed that there
was a clear increase in frataxin isoforms in themitochondrial and nucle-
ar fractions (Fig. 4B). There is only a very faint signal corresponding to
mature frataxin in the cytosol which may reﬂects the low level of ex-
pression of FXN II in these cells.
Overall, these results provide proof of principle that the iBAC-FXN
vector contains all the regulatory elements needed for proper FXN
gene expression including correct alternative splicing (for frataxin iso-
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Fig. 2. Delivery of the frataxin gene into mouse cerebellum in vivo. A herpes viral amplicon harbouring the complete frataxin genomic locus (iBAC-FXN) was injected into the mouse cer-
ebellar cortex and RNA was prepared for the analysis of FXN isoform expression. (A) Diagram showing the stereotaxic injection of the iBAC-FXN into the adult mouse cerebellum. (B) RT-
PCRdetection of frataxin isoforms at different times after injection.M: 1 kb ladder (Invitrogen); PCR−ve: negative control for PCR reactions; (+): cDNAusedas template for PCR ampliﬁed
with RT enzyme; (−): cDNA used as template for PCR ampliﬁed without RT enzyme. Numbers to the right indicate the size (in base pairs) of marker bands.
80 S. Pérez-Luz et al. / Genomics 106 (2015) 76–824. Discussion
The correct expression of distinct frataxin isoforms may be impor-
tant for the therapy of FRDA. There are still many uncertainties in our
understanding of the pathophysiology of FRDA [23], whichmay be cru-
cial for the design of an effective gene therapy approach. Little is known
about the regulation of frataxin gene expression in response to distinct
physiological and pathological conditions. The threshold level of
frataxin which causes the pathology is not well established. It is still
an open question whether the relevant level of frataxin is not that
found in the basal state but rather in states in which frataxin is up-
regulated in response to some stimuli. Furthermore, it is not clear why
frataxin deﬁciency affects selected cell types far more than others [23].
The selectivity of expression of the novel frataxin isoforms [44] mayBA
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+  - +     - +   -


















Fig. 3. Presence of frataxin isoforms in humanOMS cells fromhealthy subjects and FRDApatient
were cultured and RNA was isolated to test for FXN isoform expression. RT-PCR analysis demon
(Invitrogen); PCR−ve: negative control for PCR reactions; (+): cDNA used as template for PC
enzyme. Numbers to the right indicate the size (in base pairs) of marker bands. B) Human olfa
and then subjected to cell fractionation to test for the subcellular distribution of FXN isoforms.possibly contribute to the cellular selectivity of FRDA. Furthermore, pre-
vious studies have shown the occurrence of a cytosolic pool of frataxin
[1,6,7,22] whichmay correspond to the novel FXN II isoform [44]. Of in-
terest in this regard is the demonstration of a role for extra-
mitochondrial frataxin in the promotion of cell survival [7]. Whether
the expression of extra-mitochondrial FXN II in the cerebellum is re-
quired for correct neuronal survival and function is still an open
question.
Thus the use of the cDNA coding for the conventional mitochondrial
frataxin (FXN I) under the control of a viral promotermay not be the op-
timal approach for the gene therapy of FRDA despite the promising re-
sults obtained so far [21,30]. Moreover there is a serious concern
about the danger of frataxin overexpression, since this has been
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Fig. 4. Recovery of frataxin isoforms in human olfactory mucosa stem cells after transduction with the frataxin-containing BAC. Human olfactory mucosa stem cells obtained from FRDA
patients were cultured and transducedwith a herpes viral amplicon harbouring the complete frataxin genomic locus (iBAC-FXN). Theywere then subjected to either RNA isolation or sub-
cellular fractionation. A) RT-PCR demonstrated the expression of the different frataxin isoforms in cells before (UT) and 48 h after transduction (iBAC-FXN). M: 1 kb ladder (Invitrogen);
PCR−ve: negative control for PCR reactions; (+): cDNAused as template for PCR ampliﬁedwith RT enzyme; (−): cDNA used as template for PCR ampliﬁedwithout RT enzyme. Numbers
to the right indicate the size (in base pairs) of marker bands. B)Western blot showing the subcellular localization of the three different frataxin isoforms. Lanes 1, 3 and 5: untransduced
cells, lanes 2, 4 and 6: iBAC-FXN-transduced cells.
81S. Pérez-Luz et al. / Genomics 106 (2015) 76–82[25,43]. It thus seems that an optimal gene therapy approach for FRDA
should guarantee physiologically-regulated expression of the frataxin
gene.
Indeed, the use of large DNA molecules containing whole genomic
loci has recently received attention as an emerging alternative to the
use of cDNAs within viral vectors for gene therapy [18,31]. Studies
performed in transgenic mice have demonstrated the beneﬁts of
using large fragments of genomic DNA, which allow the delivery
of intact mammalian genes with all their regulatory elements. In this
way, a level and control of expression comparable to the endogenous
expression of the gene can be achieved. In this regard, the experience
gained fromusing yeast artiﬁcial chromosomes (YACs) and bacterial ar-
tiﬁcial chromosomes (BACs) has shown that large genomic fragments
drive tissue speciﬁc expression at physiological levels [34,37–39].
Speciﬁcally, the use of a YAC or BAC carrying the entire frataxin gene
locus has rescued frataxin knock-out mice from embryonic lethality
[34,37,38].
Amplicon vectors based on herpes simplex virus 1 (HSV-1) are one of
themost promising alternatives for the delivery of large DNAmolecules
in gene therapy protocols as they can accommodate DNA molecules as
big as 150 kb [14,31]. This makes them ideal vehicles for delivering en-
tire genomic lociwith all their regulatory elements [41,42]. Interesting-
ly, HSV vectors bearing genomic loci also exhibit the potential to drive
the production of multiple transcripts arising from transcriptional and
posttranscriptional mechanisms [15,32]. This may be particularly rele-
vant for genes to be expressed in neuronal tissues, particularly in the
cerebellum which is characterised by a predominant use of alternative
transcription and splicing to generate transcriptome diversity [24,27].
Additional advantages of using HSV-1 amplicons as gene delivery vehi-
cles include their ability to transduce both dividing and non-dividing
cells, and their ability to persist as non-integrating episomes, thus elim-
inating the risk of insertional mutagenesis in vivo [16]. Furthermore,
HSV-1 amplicon vectors are particularly well suited for gene therapy
of neurological disorders due to their outstanding ability to deliver
genes into neurons [2,16].
In the present study, we have demonstrated that the iBAC-FXN vec-
tor is capable of producing all the different frataxin isoformswhich have
recently been described [44] both in vitro in cultured cells and in vivo
after its injection into the mouse cerebellum. We have also observed
the correct expression of frataxin isoforms in patient-derived cells
after the delivery of the 135 kb human FXN genomic locus. This vector
is therefore a promising candidate for gene therapy as it likely contains
all the regulatory elements needed for physiologically-controlled gene
expression.5. Conclusions
Our results are evidence for the great potential of the iBAC system for
gene therapy involving the delivery of genomic loci whose expression is
mediated by complex splicing and promoter usage, which may be par-
ticularly relevant for transcripts expressed in the cerebellum. Thus, the
use of a gene locus which produces all frataxin isoforms may be crucial
for full restoration of frataxin expression and the recovery of neuronal
function in selected neuronal cell types.
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